InvestorsObserver
×
News Home

Should Biotechnology Stock Exelixis, Inc. (EXEL) Be in Your Portfolio Monday?

Monday, January 24, 2022 11:56 AM | InvestorsObserver Analysts

Mentioned in this article

Should Biotechnology Stock Exelixis, Inc. (EXEL) Be in Your Portfolio Monday?

The 43 rating InvestorsObserver gives to Exelixis, Inc. (EXEL) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 72 percent of stocks in the Biotechnology industry, EXEL’s 43 overall rating means the stock scores better than 43 percent of all stocks.

Overall Score - 43
EXEL has an Overall Score of 43. Find out what this means to you and get the rest of the rankings on EXEL!

What do These Ratings Mean?

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as “good” for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 43 means the stock is more attractive than 43 percent of stocks. These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

What's Happening With Exelixis, Inc. Stock Today?

Exelixis, Inc. (EXEL) stock has gained 1.85% while the S&P 500 has fallen -2.82% as of 11:46 AM on Monday, Jan 24. EXEL has gained $0.32 from the previous closing price of $17.32 on volume of 1,029,452 shares. Over the past year the S&P 500 is higher by 10.85% while EXEL has fallen -22.70%. EXEL earned $0.51 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 35.13. Click Here to get the full Stock Report for Exelixis, Inc. stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App